MAGEA4 and head and neck squamous cell carcinoma: A phase I trial investigated the safety, kinetics, and clinical effect of T lymphocytes transduced with a MAGEA4-specific T-cell receptor gene in patients with unresectable and treatment-refractory solid tumors, including HNSCC (72).